Adaptimmune Therapeutics plc ( ADAP) - Key Metrics
Stock symbol ADAP is outdated, potentially delisted? Maybe it is available on other exchange?
ADAP Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2025Q2 | $0.05 | -$0.11 | -$0.13 | -$0.13 |
| 2025Q1 | $0.03 | -$0.19 | -$0.26 | -$0.26 |
| 2024Q4 | $0.01 | -$0.29 | -$0.13 | -$0.14 |
| 2024Q3 | $0.16 | -$0.07 | -$0.21 | -$0.21 |
| 2024Q2 | $0.50 | $0.27 | $0.19 | $0.18 |
ADAP Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2025Q2 | ? | -0.52 |
| 2025Q1 | ? | -0.27 |
| 2024Q4 | ? | -0.46 |
| 2024Q3 | ? | -3.45 |
| 2024Q2 | ? | 0.97 |
ADAP
Price: $0.06
52 week price:
Earnings Per Share: -0.66 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United Kingdom
Volume: 237100
Ebitda: 858000Market Capitalization: 14.6 million